You are here: Industry Insights > Pfizer

News List

Pfizer’s Mylotarg wins EU approval for AML pharmatimes
April 26, 2018
European regulators have cleared Pfizer’s Mylotarg to treat a certain subset of patients with acute myeloid leukaemia (AML).
Pfizer vaccine receives FDA's breakthrough therapy designation biospectrumasia
April 26, 2018
As of 2016, the burden of MenB is highest in adolescents/young adults (32%) and infants (20%), followed by children ages 1 to 4 years (12%) and children ages 5 to 10 years (4%)
FDA rejects Pfizer’s Herceptin biosimilar pharmatimes
April 25, 2018
US regulators have issued a complete response letter regarding Pfizer’s filing for a biosimilar version of Roche's blockbuster cancer drug Herceptin.
P&G Acquires Merck KGaA’s Consumer Health Business, Pfizer Spurned Again biospace
April 20, 2018
Pfizer’s consumer health business has been spurned again. This time by mega-consumer goods company Proctor & Gamble.
In First Trial of New Gene Therapy Program, Pfizer Doses First Duchenne Muscular Dystrophy Patient biospace
April 16, 2018
Pfizer Inc. has dosed its first patient in a Phase Ib clinical trial of PF-06939926 for Duchenne muscular dystrophy (DMD).
Pfizer Boss Ian Read Claims They Won't Buy Bristol-Myers Squibb or Make Any Other Big Deals biospace
April 16, 2018
There has been speculation for several years whether Pfizer Inc. would consider buying Bristol-Myers Squibb. That appears to have been laid to rest by comments made by Pfizer’s chief executive officer, Ian Read.
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy biospace
April 13, 2018
Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD).
After Trial Failure, Pfizer's Inlyta Unlikely to Replace Sutent for Kidney Cancer biospace
April 12, 2018
An Independent Monitoring Committee recommended that Pfizer halt the Phase III ATLAS trial of Inlyta (axitinib) because it wasn’t proving effective.
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery biospace
April 11, 2018
Pfizer today announced that the Independent Data Monitoring Committee of the Phase III ATLAS trial evaluated INLYTA® (axitinib) as an adjunct to high-risk patients with recurrent renal cell carcinoma (RCC) after renal cell carcinoma
Pfizer Joins the TriNetX Global Research Network contractpharma
April 11, 2018
fizer Inc. has joined the TriNetX global health research network.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page